<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03572270</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-391</org_study_id>
    <secondary_id>2017-A03469-44</secondary_id>
    <nct_id>NCT03572270</nct_id>
  </id_info>
  <brief_title>HIV and Ovarian Reserve</brief_title>
  <acronym>VIHRO</acronym>
  <official_title>Evaluation of the Potential Impact of HIV and Its Treatments on Ovarian Reserve: Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent evidence suggests a decline in fertility of persons living with HIV (PLWH) (delayed
      pregnancies, sponteanous abortions, especially when patients receive an antiretroviral
      therapy, early menopause, amenorrhea and anovulatory cycles) with a possible decrease in
      ovarian reserve. However, indications of fertility preservation by freezing oocytes are
      nevertheless not clearly identified.

      The objective of this study is to evaluate the ovarian reserve before and after the
      implementation of antiretroviral treatment in PLWH for whom the diagnosis of HIV has just
      been made.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a monocentric prospective cohort study with minimal risk and constraints. Ovarian
      reserve is compared between two groups: 30 PLWH, at time of diagnosis and 6, 12 and 18 months
      after initiation of an antiretroviral therapy, and 30 HIV negative women attending medically
      assisted procreation consultation for male infertility, age, BMI and smoking habits matched.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>No masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>change from inclusion visit AMH level at 18 months</measure>
    <time_frame>M0 (inclusion visit) and M18 (after 18 months)</time_frame>
    <description>blood test to evaluate ovarian reserve thanks to AMH</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>antral follicle count</measure>
    <time_frame>Month 0 (inclusion visit), Month 6 (after 6 months), Month12 (after one year), Month18 (after 18 months)</time_frame>
    <description>pelvic ultrasound to evaluate ovarian reserve thanks to antral follicle count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>estradiol, lutenizing hormone and follicle-stimulating hormone test</measure>
    <time_frame>Month 0 (inclusion visit), Month 6 (after 6 months), Month 12 (after one year), Month18 (after 18 months)</time_frame>
    <description>blood test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>HIV</condition>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>case</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PLWH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>HIV negative women, going to medically assisted procreation consultation for male infertility</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>AMH test</intervention_name>
    <description>Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve</description>
    <arm_group_label>case</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>pelvic ultrasound</intervention_name>
    <description>Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve</description>
    <arm_group_label>case</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For every participant :

          -  woman aged 18 to 37

          -  covered by social security

          -  able to give an informed consent

        Case group only :

          -  diagnosis of HIV infection during the 3 months before inclusion

          -  concomitant initiation of an antiretroviral therapy with integrase inhibitors and
             nucleoside analogues

        Control group only :

          -  assisting medically assisted procreation consultation for male infertility

          -  matching case subjects with age, BMI and smoking habits

        Exclusion Criteria:

          -  For every participant :

          -  current pregnancy

          -  condition or associated treatment that may have an impact on fertility

          -  premature ovarian failure

          -  polycystic ovary syndrome

          -  endometriosis

        Control group only :

        - suspected HIV infection
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>37 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence BRUGNON</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick LACARIN</last_name>
    <phone>0473751195</phone>
    <email>placarin@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Patrick LACARIN</last_name>
      <phone>0473751195</phone>
      <email>placarin@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Florence BRUGNON</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine JACOMET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Sophie GREMEAU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Luc POULY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent SAPIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 29, 2018</study_first_submitted>
  <study_first_submitted_qc>June 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2018</study_first_posted>
  <last_update_submitted>June 26, 2018</last_update_submitted>
  <last_update_submitted_qc>June 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Ovarian reserve</keyword>
  <keyword>Fertility preservation</keyword>
  <keyword>Anti HIV agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

